Berta Caballol
YOU?
Author Swipe
View article: Volumetric Changes in Perianal Fistulizing Crohn's Disease Measured by Magnetic Resonance Is Feasible and Could Be a Potential Biomarker to Predict Clinical Outcomes
Volumetric Changes in Perianal Fistulizing Crohn's Disease Measured by Magnetic Resonance Is Feasible and Could Be a Potential Biomarker to Predict Clinical Outcomes Open
Background and Aim Changes in 3D volumetry of perianal fistulas in patients with Crohn's disease (CD) measured by MRI could be an imaging biomarker of interest. The objective of the study was to determine the value of volumetric changes in…
View article: TL1A-activated T cells remodel the rectal mucosa in Crohn’s disease patients with perianal fistulizing disease
TL1A-activated T cells remodel the rectal mucosa in Crohn’s disease patients with perianal fistulizing disease Open
Background Perianal fistulizing disease (PFD) is a complication that affects about 20% of Crohn’s disease (CD) patients whose etiology remains unknown. Objectives To identify predisposing events driving fistula formation. Design Rectal bio…
View article: Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients
Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients Open
Background and Aims Tofacitinib, a Janus kinase inhibitor, is approved for the treatment of moderate-to-severe ulcerative colitis. Nonetheless, 40-60% of patients will not respond adequately. The mechanisms underlying responses to tofaciti…
View article: Asymptomatic Inflammatory Bowel Disease Diagnosed During Colorectal Cancer Population Screening in Catalonia: Characteristics and Natural History
Asymptomatic Inflammatory Bowel Disease Diagnosed During Colorectal Cancer Population Screening in Catalonia: Characteristics and Natural History Open
INTRODUCTION: Inflammatory bowel disease (IBD) is usually diagnosed when symptomatic. Prognosis and evolution of preclinical IBD is largely unknown. However, colorectal cancer screening programs (CRCSP) detect a subset of patients with IBD…
View article: Understanding the mechanisms underlying the lack of response to Janus kinase inhibition in ulcerative colitis
Understanding the mechanisms underlying the lack of response to Janus kinase inhibition in ulcerative colitis Open
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. About one-third of UC patients failed to respond to available drugs, including tofacitinib, a broad Janus kinase (JAK) inhibitor. However, the mechanisms underlying pa…
View article: Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (<scp>REASUC</scp> study)
Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (<span>REASUC</span> study) Open
Summary Background The advent of new therapeutic agents and the improvement of supporting care might change the management of acute severe ulcerative colitis (ASUC) and avoid colectomy. Aims To evaluate the colectomy‐free survival and safe…
View article: P276 Predictive value of changes in 3D volumetry in perianal fistulas in patients with Crohn’s disease under biologic therapy. A pilot study
P276 Predictive value of changes in 3D volumetry in perianal fistulas in patients with Crohn’s disease under biologic therapy. A pilot study Open
Background Changes in the 3D volumetry of perianal fistulas measured by magnetic resonance (MR) could be an imaging biomarker of interest. The objective of the study is to determine the value of volumetric changes in perianal fistulas in p…
View article: Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU
Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU Open
Background: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders. Objective: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders. Design: …
View article: P516 Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes
P516 Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes Open
Background Evidence suggests that subcutaneous formulation of biosimilar infliximab (CT-P13) (SC-IFX) is capable to maintain clinical remission safely and to increase drug levels with a good acceptance in patients with Crohn’s disease (CD)…
View article: P026 Differential effects of tofacitinib on macrophage activation may contribute to lack of response in ulcerative colitis patients
P026 Differential effects of tofacitinib on macrophage activation may contribute to lack of response in ulcerative colitis patients Open
Background We previously showed that ulcerative colitis (UC) patients refractory to tofacitinib present an increase in the activation and the pro-inflammatory profile of intestinal macrophages1. However, the mechanism by which tofacitinib …
View article: P697 De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
P697 De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice. Open
Background Combination therapy with an immunomodulator (IMM) and an anti-TNF agent (specifically infliximab) is recommended in Crohn’s disease (CD) and ulcerative colitis (UC) patients to improve efficacy and reduce anti-TNF immunogenicity…
View article: P456 Magnetic resonance enterography findings at week 46 after biological treatment predict long-term clinical outcomes in Crohn’s disease patients
P456 Magnetic resonance enterography findings at week 46 after biological treatment predict long-term clinical outcomes in Crohn’s disease patients Open
Background Magnetic resonance enterography (MRE) provides an accurate evaluation of transmural lesions in Crohn’s Disease (CD). However, MRE findings associated with poor long-term outcomes in CD are not yet defined. Identification of such…
View article: P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study) Open
Background The advent of new therapeutic agents and the improvement of supporting care might change the management of acute severe ulcerative colitis (ASUC) to avoid colectomy and change the natural history of the disease. The effectivenes…
View article: DOP65 T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn’s Disease patients with perianal fistulizing disease
DOP65 T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn’s Disease patients with perianal fistulizing disease Open
Background Perianal fistulizing disease (PFD) is a complication occurring in about 20% of Crohn’s Disease (CD) patients. It consists of the formation of new epithelised tracks connecting the intestine with the outer perianal region, which …
View article: OP23 Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia
OP23 Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia Open
Background Background: It has been postulated that early treatment of inflammatory bowel disease (IBD) is associated with a better long-term response. In Catalonia, the early detection program for colorectal cancer (EDPCRC) has been active…
View article: Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII) Open
(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infec…
View article: Predictors of bowel damage in the long-term progression of Crohn’s disease
Predictors of bowel damage in the long-term progression of Crohn’s disease Open
BD, as assessed by the LI, progressed in half of the patients with CD over a period of 5-12 years. The main determinants of BD progression were ileal location, stricturing/fistulizing phenotype, and disease duration.
View article: Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?
Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue? Open
(1) Background: Fecal calprotectin (FC) correlates well with colonic inflammatory activity of Crohn’s disease (CD); data about relation of FC and small bowel (SB) lesions are still contradictory. The main aim was to analyze the relationshi…
View article: Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry Open
We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in th…
View article: P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients? Open
Background Ulcerative proctitis may have a mild and less aggressive course, although evidence is scarce because these patients are excluded from participation in randomized controlled clinical trials. The aim is to identify clinical charac…
View article: P523 Effectiveness of biological treatments for inflammatory bowel disease in the elderly patients
P523 Effectiveness of biological treatments for inflammatory bowel disease in the elderly patients Open
Background Biological treatments used for the treatment of inflammatory bowel disease (IBD) have demonstrated their efficacy and safety, although these results were obtained from studies that mostly include young people generally included …
View article: P575 Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results
P575 Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results Open
Background Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for patients with refractory Crohn’s disease [CD]. Although the safety of the procedure has been improved over the last decade, AHSCT is still b…
View article: P481 Profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease
P481 Profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease Open
Background The use of biological drugs for the treatment of IBD in elderly patients is becoming more frequent in our environment. However, given the greater risk of these patients to develop related adverse effects, the profile of the pati…
View article: Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature
Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature Open
Ustekinumab, a monoclonal antibody against interleukin (IL)-12 and IL-23 approved for the treatment of Crohn’s disease, has shown to be an effective therapy with a favourable safety profile. Clinical trials and real-world studies have repo…
View article: DOP04 Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU)
DOP04 Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU) Open
Background Limited data is available of the outcome of inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT). The aim of our study was to describe the natural history of pre-existing IBD and de novo IBD after …
View article: P349 Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU)
P349 Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU) Open
Background Inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT) is associated with a greater complexity in their medical management. The aim of this study was to evaluate the safety profile of different IBD t…
View article: P410 Safety of biological drugs for inflammatory bowel disease in elderly patients
P410 Safety of biological drugs for inflammatory bowel disease in elderly patients Open
Background The most feared adverse events related to biological treatment in patients with inflammatory bowel disease (IBD) are the development of tumors and / or serious infections. These events are generally more frequent in elderly pati…
View article: Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression
Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression Open
View article: DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study
DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study Open
Background The information regarding IBD patients with COVID-19 suggests that the factors related to bad outcome are older age and comorbidity whereas immunosuppressants do not have a significant impact worsening the disease evolution. To …
View article: P458 Effectiveness of biological therapy for pouchitis and other inflammatory complications ot the pouch. And the question of a second Anti-TNF after failure? Results from the RESERVO Study of GETECCU
P458 Effectiveness of biological therapy for pouchitis and other inflammatory complications ot the pouch. And the question of a second Anti-TNF after failure? Results from the RESERVO Study of GETECCU Open
Background Pouchitis and Crohn′s-like disease of the pouch (CDP) can be refractory to conventional therapy. Evidence of biological therapy has been rarely reported in large patient cohorts. We explored the use and effectiveness of these th…